Early Posttransplant Blood Transfusion and Risk for Worse Graft Outcomes

Reem Daloul1, Juarez R. Braga2, Alejandro Diez1, April Logan1 and Todd Pesavento1

1The Ohio State University Medical Center, Columbus, Ohio, USA; and 2Institute for Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada

Introduction: Blood transfusion is a risk factor for allosensitization. Nevertheless, blood transfusion posttransplant remains a common practice. We evaluated the effect of posttransplant blood transfusion on graft outcomes.

Methods: We included nonsensitized, first-time, kidney-alone recipients transplanted between 1 July 2015 and 31 December 2017. Patients were grouped based on receiving blood transfusion in the first 30 days posttransplant. The primary end point was a composite outcome of biopsy-proven acute rejection, death of any cause, or graft failure in the first year posttransplant. Secondary outcomes included the individual components of the primary outcome and the cumulative incidence of de novo donor-specific antibodies (DSAs).

Results: Two hundred seventy-three patients were included. One hundred twenty-seven (47%) received blood transfusion. Patients in the transfusion group were more likely to be older, have had a deceased donor, and have received induction with basiliximab. There was no difference between groups in the composite primary outcome (adjusted hazard ratio \( \text{HR} = 1.34; 95\% \text{ confidence interval [CI],} 0.83–2.17; P = 0.23\)). The cumulative incidence of de novo DSAs during the first year posttransplant was similar between groups (12.8% transfusion vs. 10.9% no transfusion, \( P = 0.48\)).

Conclusion: Early transfusion of blood products in kidney transplant recipients receiving induction with lymphocyte depletion was not associated with an increased hazard of experiencing acute rejection, death from any cause, or graft loss.

Kidney Int Rep (2021) 6, 986–994; https://doi.org/10.1016/j.ekir.2020.12.038

KEYWORDS: donor-specific antibodies; kidney transplant; rejection; transfusion

ª 2021 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

See Commentary on Page 875

Sensitization to human leukocyte antigens (HLAs) remains a critical obstacle to successful transplantation.1–7 Over the last decade, there has been a significant effort by the transplant community to prevent and control the production of HLA antibodies before and after organ transplantation.

Pregnancy, blood product transfusion, and previous organ transplantation have been associated with the development of HLA sensitization. Kidney transplant candidates are at particularly increased risk for sensitization from blood transfusion because of the high prevalence of anemia associated with kidney disease.8 Exposure to HLA antigens on the surface of red blood cells and leukocytes has been associated with not only the development of new anti-HLA antibodies but also an increase in the breadth of the preexisting antibody profile, measured by calculated panel reactive antibody.9,10 The use of leukocyte-reduced blood products does not seem to eliminate such a risk.11–13

International guidelines for the management of anemia in patients with chronic kidney disease have been established to standardize anemia treatment and promote a reduction in blood transfusion.14 These guidelines explicitly call for avoiding the administration of blood products in patients eligible for organ transplantation.

This universal consensus regarding the need to avoid blood products in kidney transplant candidates does not extend into similar cautionary calls in the posttransplant setting. Blood product transfusions are used frequently in transplant recipients, especially in the early posttransplant period. Such a difference in clinical practice might stem from the presumption that the risk for allosensitization after transfusion of blood products is mitigated by concomitant use of immunosuppressive induction and maintenance drugs.15

To date, only a few retrospective studies have evaluated the immunologic safety of posttransplant...
blood transfusion. These reports had conflicting results in terms of the risk for acute rejection and graft and patient survival. Therefore, we aimed to evaluate whether the transfusion of blood products was indeed associated with an increased risk for acute rejection, graft loss, or death by any cause in nonsensitized kidney transplant recipients on maintenance immunosuppressive therapy.

**METHODS**

**Study Design and Participants**

This was a retrospective cohort study that included nonsensitized adults who received either a deceased or a living donor kidney transplant at our center between 1 July 2015 and 31 December 2017. We excluded patients who had any historic evidence of HLA sensitization defined as calculated panel reactive antibody >0% and/or panel reactive antibody class I or class II >0%, had a previous organ transplantation, or had a kidney transplantation combined with other solid organ.

The clinical and research activities being reported are consistent with the Principles of the Declaration of Istanbul as outlined in the Declaration of Istanbul on Organ Trafficking and Transplant Tourism.

**Main Exposure**

The main exposure was a transfusion of any blood product performed within 30 days after transplantation. We chose this definition based on published literature suggesting that the majority of blood transfusions occur within the first month after transplantation. Only leukocyte-reduced blood products are used for transfusion in kidney transplant recipients at our center. Patients were divided into 2 groups: (1) early posttransplant transfusion and (2) no early transfusion. A blood transfusion was confirmed based on a review of records from the blood bank and individual patients’ chart review. For patients who received multiple blood transfusions, the date of the first transfusion was used to categorize study participants.

**Immunosuppressive Therapies**

Most patients received induction therapy with a lymphocyte-depleting agent, either thymoglobulin or alemtuzumab, in compliance with our center’s protocol. In a minority of patients, an interleukin 2 receptor antagonist (basiliximab) was used. All patients had early steroid withdrawal by day 7 postransplant unless the patient was on chronic prednisone therapy before transplant. Maintenance immunosuppression was achieved with variable dual immunosuppressive therapy combinations including a calcineurin inhibitor, mammalian target of rapamycin inhibitors, antimetabolites, and/or belatacept therapy.

**Outcomes**

The primary outcome was the composite of biopsy-proven acute rejection, death of any cause, or graft loss in the first 12 months after transplant. Secondary outcomes included the individual components of the composite outcome and the cumulative incidence of developing de novo DSAs during the first year after transplant. A rejection episode was defined as any episode of biopsy-proven acute cellular, antibody-mediated, mixed, or borderline cellular rejection of the transplanted kidney according to the Banff 2013 histopathologic classification. All biopsies were for cause. Graft loss was defined as a return to dialysis or retransplantation at any time after the initial transplant episode. DSAs were identified using Luminex solid phase assay (One Lambda, Canoga Park, CA) with a mean fluorescence intensity cutoff of 1000. Posttransplant DSA screening was performed on a for-cause basis.

**Statistical Analysis**

A descriptive analysis was performed comparing baseline characteristics between the exposure groups. Continuous variables were expressed as median (25th–75th percentile) and compared with the Mann-Whitney U test. Categoric variables were expressed as the absolute number (proportion) and compared using the chi-square statistic. To avoid immortal time bias when defining time-based exposure groups, we used a landmark design. The landmark was set at 30 days after the date of the renal transplantation. Patients who died before 30 days were excluded. Outcomes were assessed from day 30 after transplant until the end of follow-up on 30 June 2019. We used inverse probability of treatment weighting (IPTW) with weights derived from the propensity score to estimate the effect of transfusion in recipients of a kidney transplantation on the hazard of the composite outcome. The propensity score was created using a logistic regression model for the predicted probability of receiving a blood transfusion as a function of 25 variables (Supplementary Appendix S1). IPTW-weighted adjusted survival curves and the log-rank test were used to compare outcomes between groups according to the exposure. Log-rank tests were used to evaluate the occurrence and time to an event between the transfusion and no transfusion group. We used the IPTW-weighted Cox proportional hazard model to calculate adjusted HRs with associated 95% Wald CIs for the transfusion group using no transfusion as the reference category. Additionally, the cumulative incidence function was
used to evaluate the incidence of de novo DSAs, treating death of any cause as a competing event.24 A 2-sided \( P < .05 \) was considered statistically significant. All analyses were performed with SAS University Edition software (SAS Institute Inc, Cary, NC).

**Ethics Approval**

Institutional research board approval was obtained from The Ohio State University Biomedical Sciences Institutional Review Board (2018H0510) before the initiation of data collection.

**RESULTS**

**Study Cohort**

We identified 598 kidney recipients between 2015 and 2017. The application of the inclusion and exclusion criteria resulted in a cohort of 274 individuals (Figure 1). One patient died with a functioning graft (Figure 1). One patient died with a functioning graft and was excluded due to the landmark analysis. There was no other graft loss or loss to follow-up within the first month after transplant. In total, 273 patients were included in the final analysis.

**Baseline Clinical Characteristics**

Of 273 individuals, 127 (47%) received at least 1 blood product transfusion (33 receiving only intraoperative transfusion, 69 receiving only postoperative transfusion, and 25 receiving both intraoperative and postoperative transfusion), and 146 (53%) did not receive blood products within 1 month after transplantation. Of the 127 individuals who had a transfusion, 6 (5%) received both platelets and packed red blood cells. The median hemoglobin at the time of transfusion was 7.1 g/dl (25th–75th percentile = 6.7–7.5). The median time to transfusion after transplantation was 4.5 days (25th–75th percentile = 2.0–15.0). The most common indication for blood transfusion was an acute drop in hemoglobin to a level below 8 g/dl or asymptomatic anemia with hemoglobin < 7 g/dl. Approximately 63% of patients received a blood transfusion within the first week posttransplantation, and 65% received multiple blood transfusions on several days. The median number of transfused blood products units was 2 (25th–75th percentile = 1–3). Patients were followed for a median time of 1024 days (25th–75th percentile = 824–1258).

Patients who received blood product transfusion were older, received more deceased donors, and had a higher creatinine at 1 month posttransplant. More patients in the transfusion group were discharged on maintenance immunosuppressive therapy with a combination of a calcineurin inhibitor and antimetabolites compared with a combination of a calcineurin inhibitor and a mammalian target of rapamycin inhibitor in the no transfusion group (Table 1).

**Primary Outcome**

The primary outcome occurred in 26 patients (20.5%) in the transfusion group and in 11 patients (7.5%) in the no transfusion group (Table 2). Compared with no transfusion, individuals who received a transfusion in the early period after transplantation had a statistically significant higher hazard of experiencing biopsy-proven acute rejection, death from any cause, or graft loss according to the unadjusted analysis (HR = 2.91; 95% CI, 1.44–5.89; \( P < .05 \)). However, in the IPTW-weighted analysis, blood transfusion was not associated with an increased risk for the composite outcome of biopsy-proven acute rejection, death from any cause, or graft failure (IPTW HR = 1.34; 95% CI, 0.83–2.17; \( P = 0.233 \)) (Figure 2).

**Secondary Outcomes of Death, Allograft Survival, and Acute Rejection**

A total of 5 individuals (3.9%) who received a transfusion and 2 (1.4%) who did not receive a transfusion died during the first year after transplant. The most common cause of death was sepsis (n = 3). There were 2 suicides (including the patient who died during the 30-day transfusion window). There was no statistically significant difference in the risk for death from any cause between both groups (unadjusted HR = 2.90; 95% CI, 0.56–14.95; \( P = 0.20 \); IPTW weighted HR = 1.04; 95% CI, 0.31–3.52, \( P = 0.95 \)) (Figure 3).

A total of 16 patients experienced acute rejection in the first 30 days after transplant (Supplementary Table S1). The cumulative incidence of acute
| Variable | Overall (N = 273) | Transfusion (n = 127) | No transfusion (n = 146) | P value |
|----------|-------------------|-----------------------|--------------------------|---------|
| Recipient characteristics | | | | |
| Age, median (25th–75th) | 55 (43–62) | 57 (47–63) | 52 (40–61) | 0.0127 |
| Female sex, n (%) | 78 (29) | 41 (32) | 37 (25) | 0.2280 |
| Race, n (%) | | | | 0.5402 |
| White | 197 (72) | 90 (71) | 107 (73) | |
| Black | 56 (21) | 30 (24) | 26 (18) | |
| Asian | 5 (2) | 2 (2) | 3 (2) | |
| Others | 15 (5) | 5 (4) | 10 (7) | |
| Cause of ESRD, n (%) | | | | 0.1473 |
| Diabetes | 92 (34) | 52 (41) | 40 (27) | |
| Hypertension | 70 (26) | 29 (23) | 41 (28) | |
| IgA nephropathy | 21 (8) | 7 (6) | 14 (10) | |
| Polycystic kidney disease | 17 (6) | 6 (5) | 11 (8) | |
| Other | 73 (27) | 33 (26) | 40 (27) | |
| Year of transplant, n (%) | | | | 0.2542 |
| 2015 | 59 (22) | 33 (26) | 26 (18) | |
| 2016 | 114 (42) | 51 (40) | 63 (43) | |
| 2017 | 100 (37) | 43 (34) | 57 (39) | |
| Organ donor type, n (%) | | | | 0.0005 |
| Living | 113 (41) | 37 (29) | 76 (52) | |
| Deceased brain death | 122 (45) | 67 (53) | 55 (38) | |
| Deceased cardiac death | 38 (14) | 23 (18) | 15 (10) | |
| Total HLA mismatches, n (%) | | | | 0.6841 |
| 0 | 42 (15) | 18 (14) | 24 (16) | |
| 1 | 3 (1) | 1 (1) | 2 (1) | |
| 2 | 15 (6) | 4 (3) | 11 (8) | |
| 3 | 41 (15) | 19 (15) | 22 (15) | |
| 4 | 60 (22) | 30 (24) | 30 (21) | |
| 5 | 71 (26) | 33 (26) | 38 (26) | |
| 6 | 41 (15) | 22 (17) | 19 (13) | |
| DR mismatches, n (%) | | | | 0.4985 |
| 0 | 64 (23) | 26 (20) | 38 (26) | |
| 1 | 118 (43) | 59 (46) | 59 (40) | |
| 2 | 91 (33) | 42 (33) | 49 (34) | |
| Donor/recipient CMV status, n (%) | | | | 0.7064 |
| D+/R− | 71 (26) | 37 (30) | 34 (24) | |
| D+/R+ | 75 (28) | 35 (28) | 40 (28) | |
| D−/R+ | 47 (18) | 21 (17) | 26 (18) | |
| D−/R− | 75 (28) | 32 (26) | 43 (30) | |
| Induction, n (%) | | | | 0.0173 |
| ATG | 250 (91) | 115 (91) | 135 (92) | |
| ATG and basiliximab | 7 (3) | 4 (3) | 3 (2) | |
| Basiliximab | 8 (3) | 7 (6) | 1 (1) | |
| Alemtuzumab | 8 (3) | 1 (1) | 7 (5) | |
| Maintenance immunosuppression, n (%) | | | | 0.0041 |
| CNI/antimetabolites | 68 (25) | 40 (31) | 28 (19) | |
| CNImTORi | 174 (64) | 67 (53) | 107 (73) | |
| mTORi/antimetabolites | 27 (10) | 17 (13) | 10 (7) | |
| Belatacept | 4 (1) | 3 (2) | 1 (1) | |
| AlloScreen checked in the first year after transplant, n (%) | 214 (78) | 102 (80) | 112 (77) | 0.6805 |
| Number of AlloScreen tests performed in the first year, median (25th–75th) | 3 (2–5) | 3 (2–5) | 3 (2–5) | 0.6818 |
| 30-day creatinine, median (25th–75th) | 1.71 (1.41–2.32) | 1.81 (1.39–2.04) | 1.65 (1.43–2.07) | 0.0259 |
| 180-day creatinine, median (25th–75th) | 1.62 (1.26–1.94) | 1.62 (1.21–1.93) | 1.62 (1.30–1.96) | 0.7726 |
| 365-day creatinine, median (25th–75th) | 1.51 (1.25–1.91) | 1.51 (1.22–1.97) | 1.50 (1.27–1.91) | 0.7246 |
| 30-day eGFR, median (25th–75th) | 43.01 (30.50–55.85) | 40.10 (22.99–55.85) | 44.63 (34.58–55.96) | 0.0105 |
| 180-day eGFR, median (25th–75th) | 47.13 (37.56–59.48) | 46.94 (37.59–59.60) | 47.53 (37.38–58.85) | 0.6882 |

(Continued on following page)
rejection was higher in the transfusion group in the unadjusted analysis (16.4% in transfusion and 5.5% in no transfusion, \( P < 0.05 \)) but not in the IPTW-weighted analysis (IPTW weighted 12.4% in transfusion and 8.3% in no transfusion, \( P = 0.11 \)) (Figure 4a). Death-censored graft failure was similar between the groups (unadjusted 1.6% in transfusion and 0.7% no transfusion, \( P = 0.49 \); IPTW weighted 1.0% in transfusion and 0.8% no transfusion, \( P = 0.79 \)) (Figure 4b).

### Secondary Outcomes of DSAs

The majority of patients (78%) had at least 1 AlloScreen (LABScreen, One Lambda) test checked during the first year posttransplantation. There was no difference between the 2 groups in the number of patients who had an AlloScreen test completed (transfusion 80% vs. no transfusion 77%, \( P = 0.66 \)) or the median numbers of AlloScreen tests performed (median [25th–77th percentile] = 3 [2–5], \( P = 0.88 \)).

Among patients who received a transfusion, 19 individuals developed de novo DSAs by the end of the first year compared with 17 in the no transfusion group. There was no significant difference in the cumulative incidence of de novo DSAs between the groups (unadjusted 15.0% in transfusion and 11.6% in no transfusion, \( P = 0.38 \); IPTW weighted 12.8% in transfusion and 10.9% in no transfusion, \( P = 0.48 \)) (Figure 4c). There was also no significant difference in the DSA class between groups for individuals who developed de novo DSAs (Table 2). HLA locus specificity and the mean fluorescence intensity of de novo DSAs are listed in Supplementary Tables S2 and S3. Additionally, in patients who had an AlloScreen checked in the first year posttransplant, a similar proportion of patients developed non-DSA HLA antibodies in both groups (transfusion 30% vs. no transfusion 23%, \( P = 0.29 \)).

### Table 2. 1-year study outcomes, number of events according to transfusion in the early posttransplant period, hazard ratio with Wald 95% confidence intervals using no transfusion within 30 days as reference, and summary of donor-specific antibody (DSA) type

| Outcome                              | Transfusion (n = 127) | No transfusion (n = 146) | Hazard ratio (95% confidence interval) or cumulative incidence (%) | Cox or Gray P value | Hazard ratio (95% confidence interval) or cumulative incidence (%) | Cox or Gray P value |
|--------------------------------------|-----------------------|--------------------------|-----------------------------------------------------------------|---------------------|-----------------------------------------------------------------|---------------------|
| **Primary outcome, n (%)**           |                       |                          |                                                                 |                     |                                                                 |                     |
| Death from any cause, graft loss,    | 26 (20.5)             | 11 (7.5)                 | 2.91 (1.44–5.89)                                                | 0.0030              | 1.34 (0.83–2.17)                                                | 0.2269              |
| or any type of rejection              |                       |                          |                                                                 |                     |                                                                 |                     |
| **Secondary outcomes, n (%)**        |                       |                          |                                                                 |                     |                                                                 |                     |
| Death from any cause                 | 5 (3.9)               | 2 (1.4)                  | 2.90 (0.56–14.96)                                               | 0.2032              | 1.04 (0.31–3.52)                                                | 0.9517              |
| Biopsy-proven rejection              | 21 (16.5)             | 8 (5.5)                  | Yes: 16.4%                                                     | 0.0052              | Yes: 12.4%                                                     | 0.1137              |
|                                       |                       |                          | No: 5.5%                                                       |                     |                                                                 |                     |
| **Cellular**                         | 16 (76.2)             | 6 (75.0)                 |                                                                 |                     |                                                                 |                     |
| **Antibody mediated**                | 1 (4.8)               | 1 (12.5)                 |                                                                 |                     |                                                                 |                     |
| **Mixed**                            | 0 (0.0)               | 0 (0.0)                  |                                                                 |                     |                                                                 |                     |
| **Borderline**                       | 4 (19.0)              | 1 (12.5)                 |                                                                 |                     |                                                                 |                     |
| **Graft loss**                       | 2 (1.6)               | 1 (0.7)                  | Yes: 1.6%                                                     | 0.4904              | Yes: 1.0%                                                     | 0.7877              |
|                                       |                       |                          | No: 0.7%                                                       |                     |                                                                 |                     |
| **De novo DSAs**                     | 19 (15.0)             | 17 (11.6)                | Yes: 15.1%                                                     | 0.3832              | Yes: 12.8%                                                     | 0.4790              |
|                                       |                       |                          | No: 11.5%                                                      |                     |                                                                 |                     |
| **DSA type, n (%)**                  |                       |                          |                                                             |                     |                                                                 |                     |
| Class I                              | 5 (20)                | 3 (9)                    |                                                             | 0.3895              |                                                                 |                     |
| Class II                             | 14 (56)               | 23 (72)                  |                                                             |                     |                                                                 |                     |
| Class I and II                       | 6 (24)                | 6 (19)                   |                                                             |                     |                                                                 |                     |

**IPTW**, inverse probability of treatment weighting.
DISCUSSION

In this single-center study of 273 nonsensitized kidney transplant recipients, we examined whether early transfusion of blood products was associated with worse clinical outcomes and allosensitization. Our data revealed that the transfusion of blood products within the first 30 days after transplantation was not associated with an increased rate of the composite primary outcome of biopsy-proven acute rejection, death from any cause, or graft loss in comparison with patients who did not receive an early blood transfusion. Additionally, early posttransplant transfusion of blood products was not associated with an increased incidence of de novo DSAs.

Interestingly, patients who received transfusion had a higher serum creatinine at 30 days posttransplantation. This could be a reflection of the higher number of deceased donors in this group. A worse graft function during the first month posttransplant could also explain the slower recovery of blood counts and the higher need for transfusion in this group.

Our study results are consistent with some of the previously published reports. Scornik et al. examined the effect of transfusion in 746 kidney and kidney pancreas transplant recipients. They reported a comparable frequency of posttransplant transfusion in 45% of the patients, with 80% of the transfusions occurring in the first month posttransplantation. Similar to our study, Scornik et al. found the incidence of rejection and graft loss to be similar between patients who did or did not receive blood products. Additionally, in a subset of 199 recipients who were tested for posttransplant antibodies, the incidence of DSA did not differ between transfused and nontransfused patients. Interestingly, patients included in this report received non–leukocyte-depleted blood products. Such products carry a theoretically higher potential for alloimmunization because of the higher content of white blood cells. However, it is worth noting that Scornik et al. used the less sensitive FlowPRA assay for DSA detection, which might have affected the accuracy of their DSA data.

In another report, Verghese et al. examined a cohort of 482 pediatric kidney transplant recipients and found patient survival, risk for acute rejection, and DSA-free survival to be similar in patients who received blood transfusion compared with those who did not. In a subcohort of 134 pediatric recipients who received DSA testing using solid-phase, single antigen bead assay, blood transfusion was not associated with an increased risk for antibody-mediated rejection or de novo DSAs. In this study, similar to our study, patients received lymphocyte-depleting induction therapy.

Our findings contrast with 2 recent reports. In a study by Ferrandiz et al., blood transfusion given within 12 months from transplant was associated with an increased risk for antibody-mediated rejection and de novo DSA formation in the first year after transplantation. The discrepancy compared with our results could be potentially explained by differences in the use of induction therapy and study design. In our study, 97% of patients received lymphocyte-depleting induction therapy versus 9.2% in the report by Ferrandiz et al.; lymphocyte depletion therapy has been shown to decrease the risk for biopsy-proven acute
rejection and might have provided additional protection against transfusion-induced allosensitization. Additionally, Ferrandiz et al. included patients who received blood products beyond the first month post-transplant (up to 1 year), during which time the intensity of immunosuppressive therapies tends to decrease.

Similarly, a more recent study by Hassan et al. found posttransplant blood transfusion to be associated with a higher risk of allograft failure, all rejection, and de novo DSA formation. Their study also suggested that posttransplant blood transfusion could evoke de novo DSAs. The majority of kidney transplant recipients in this study received lymphocyte depletion with alemtuzumab followed by single-agent maintenance therapy with tacrolimus. The use of tacrolimus monotherapy represents a strategy of immunosuppression minimization. The combination of alemtuzumab with immunosuppression therapy minimization has been clearly associated with inferior allograft outcomes and an increased risk for chronic allograft injury. The use of such an immunosuppressive regimen might have made recipients of blood transfusion more susceptible to allosensitization from the blood product and contributed to the inferior outcomes noted in the blood transfusion group. Additionally, in this study, 86 recipients had HLA typing of at least 1 blood donor. Forty-six of these patients developed de novo DSAs. Interestingly, transfusion-specific antibodies for the blood donor HLA antigens occurred mainly in patients who also developed DSAs (40/46, 87%) compared with patients who remained DSA free (3/40, 7.5%). Patients who developed de novo DSAs had the traditional risk factors associated with increased alloimmunization compared with the DSA-negative group such as younger age, higher proportion of simultaneous kidney-pancreases recipients, and higher degree of donor-recipient HLA mismatch. Such observation suggests that the development of transfusion-specific antibodies similar to the development of DSAs was the result of under-immunosuppression rather than the trigger that evoked de novo DSA production.

The current potent immunosuppressive therapies are capable of averting an alloimmune response to the large load of allo-HLA antigens carried on the tissues of the renal allografts. It seems reasonable that these immunosuppressive therapies will be equally effective in obviating a similar alloimmune response to the allogenic HLA antigens presented on the surface of blood products. Hence, we agree with the presumption that exposure to allo-HLA antigens in the context of blood transfusion does not lead to allosensitization if it occurred under the condition of adequate immunosuppressive therapies.
Our study has several strengths. First, we included only nonsensitized patients to avoid the confounding effect of pretransplant sensitization on graft outcomes and risk for rejection. Second, we used a landmark analysis to estimate unbiased survival probabilities conditional on exposure to a blood product, whereas previous studies have used a naive analysis neglecting the perils of time-dependent exposures. Third, we used IPTW using the propensity score to adequately adjust for the inherent treatment bias in nonrandomized observational studies.

Nevertheless, our study also has limitations that deserve consideration. First, the enrollment of nonsensitized patients decreased our sample size substantially. As a consequence, we observed wide CIs around the point estimates affecting the precision of our findings. Additionally, the inclusion of nonsensitized patients only might limit the applicability of our findings to patients with established pretransplant sensitization. Previous reports have suggested that blood transfusion might have a stronger sensitizing effect in patients with previous exposure to alloantigens. Second, patients underwent for-cause rather than routine DSA screening. This might have reduced the detected incidence of de novo DSAs among study participants. Lastly, our study evaluated the risks associated with early perioperative blood transfusion and might not necessarily extend to blood transfusion received later in the posttransplant period.

In summary, in recipients of a kidney-only transplant, early transfusion of blood products was not associated with an increased hazard of experiencing biopsy-proven acute rejection, death from any cause, or graft loss nor was it associated with an increased cumulative incidence of de novo DSAs in comparison with patients who did not receive a blood transfusion. Despite increased exposure to non–self-HLA antigen on blood products, our study supports the notion that the risk for alloimmunization related to blood transfusion in the early perioperative period is probably small when lymphocyte depletion and modern immunosuppression maintenance regimens are used.

**DISCLOSURE**

All the authors declared no competing interests.

**AUTHOR CONTRIBUTIONS**

RD was the principle investigator and participated in the research design, data collection, data analysis, and writing of the manuscript. JR Bl participated in statistical analysis and writing manuscript. AD participated in writing and reviewing the manuscript. AL participated in statistical analysis and writing the manuscript. TP participated in writing and reviewing the manuscript.

**SUPPLEMENTARY MATERIAL**

Supplementary File (PDF)

**Appendix S1. Variables included in propensity score IPTW**

**Table S1. Rejection, death, and graft loss prior to 30-day landmark**

**Table S2. HLA loci in patients who developed DSA within a year**

**Table S3. Summary of HLA loci MFI for patients who developed DSA within a year**

**REFERENCES**

1. Aubert O, Loupy A, Hidalgo L, et al. Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients. *J Am Soc Nephrol.* 2017;28:1912–1923.

2. Guidicelli G, Guerville F, Lepreux S, et al. Non-complement-binding de novo donor-specific anti-HLA antibodies and kidney allograft survival. *J Am Soc Nephrol.* 2016;27:815–825.

3. Huber L, Lachmann N, Niemann M, et al. Pretransplant virtual PRA and long-term outcomes of kidney transplant recipients. *Transpl Int.* 2015;28:710–719.

4. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. *J Am Soc Nephrol.* 2010;21:1398–1406.

5. Lim WH, Chapman JR, Wong G. Peak panel reactive antibody, cancer, graft, and patient outcomes in kidney transplant recipients. *Transplantation.* 2015;99:1043–1050.

6. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. *N Engl J Med.* 2013;369:1215–1226.

7. Otten HG, Verhaar MC, Borst HP, Hene RJ, van Zuijen AD. Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. *Am J Transplant.* 2012;12:1618–1623.

8. Ibrahim HN, Skeans MA, Li O, Ishani A, Snyder JJ. Blood transfusions in kidney transplant candidates are common and associated with adverse outcomes. *Clin Transplant.* 2011;25:653–659.

9. Leffell MS, Kim D, Vega RM, et al. Red blood cell transfusions and the risk of allosensitization in patients awaiting primary kidney transplantation. *Transplantation.* 2014;97:525–533.

10. Yabu JM, Anderson MW, Kim D, et al. Sensitization from transfusion in patients awaiting primary kidney transplant. *Nephrol Dial Transplant.* 2013;28:2908–2918.

11. Balasubramaniam GS, Morris M, Gupta A, Mesa IR, Thuraisingham R, Ashman N. Allosensitization rate of male patients awaiting first kidney grafts after leuko-depleted blood transfusion. *Transplantation.* 2012;93:418–422.

12. Karpinski M, Pochinco D, Dembinski I, Laidlaw W, Zacharias J, Nickerson P. Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates. *J Am Soc Nephrol.* 2004;15:818–824.

13. Scornik JC. Leukoreduced blood and sensitization of organ transplant candidates. *Transfusion.* 2012;52:1838–1839. author reply 1839.
14. Kliger AS, Foley RN, Goldfarb DS, et al. KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. *Am J Kidney Dis*. 2013;62:849–859.

15. Scornik JC, Meier-Kriesche HU. Blood transfusions in organ transplant patients: mechanisms of sensitization and implications for prevention. *Am J Transplant*. 2011;11:1785–1791.

16. Ferrandiz I, Congy-Jolivet N, Del Bello A, et al. Impact of early blood transfusion after kidney transplantation on the incidence of donor-specific anti-HLA antibodies. *Am J Transplant*. 2016;16:2661–2669.

17. Scornik JC, Schold JD, Bucci M, Meier-Kriesche HU. Effects of blood transfusions given after renal transplantation. *Transplantation*. 2009;87:1381–1386.

18. Verghese P, Gillingham K, Matas A, Chinnakotla S, Chavers B. Post-transplant blood transfusions and pediatric renal allograft outcomes. *Pediatr Transplant*. 2016;20:939–945.

19. Fidler S, Swaminathan R, Lim W, et al. Peri-operative third party red blood cell transfusion in renal transplantation and the risk of antibody-mediated rejection and graft loss. *Transpl Immunol*. 2013;29:22–27.

20. Hassan S, Regan F, Brown C, et al. Shared alloimmune responses against blood and transplant donors result in adverse clinical outcomes following blood transfusion post-renal transplantation. *Am J Transplant*. 2019;19:1720–1729.

21. Gleiss A, Oberbauer R, Heinz G. An unjustified benefit: immortal time bias in the analysis of time-dependent events. *Transpl Int*. 2018;31:125–130.

22. Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. *Stat Med*. 2013;32:2837–2849.

23. Xie J, Liu C. Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. *Stat Med*. 2005;24:3089–3110.

24. Zhang M-J, Zhang X, Scheike TH. Modeling cumulative incidence function for competing risks data. *Expert Rev Clin Pharmacol*. 2008;1:391–400.

25. Tanriover B, Jaikaransingh V, MacConmara MP, et al. Acute rejection rates and graft outcomes according to induction regimen among recipients of kidneys from deceased donors treated with tacrolimus and mycophenolate. *Clin J Am Soc Nephrol*. 2016;11:1650–1661.

26. Tanriover B, Zhang S, MacConmara M, et al. Induction therapies in live donor kidney transplantation on tacrolimus and mycophenolate with or without steroid maintenance. *Clin J Am Soc Nephrol*. 2015;10:1041–1048.

27. Ciancio G, Gaynor JJ, Guerra G, et al. Randomized trial of three induction antibodies in kidney transplantation: long-term results. *Transplantation*. 2014;97:1128–1138.

28. Zachariah M, Nader ND, Brar J, et al. Alemtuzumab and minimization immunotherapy in kidney transplantation: long-term results of comparison with rabbit anti-thymocyte globulin and standard triple maintenance therapy. *Transplant Proc*. 2014;46:94–100.